, Tracking Stock Market Picks
Enter Symbol:
Dendreon Corporation (DNDN) [hlAlert]

up 5,863.63 %

Dendreon Corporation (DNDN) rated Underperform by BofA/Merrill

Posted on: Wednesday,  Jul 11, 2012  10:25 AM ET by BofA/Merrill

BofA/Merrill rated Underperform Dendreon Corporation (NASDAQ: DNDN) on 07/11/2012, when the stock price was $6.56. Since
then, Dendreon Corporation has lost 98.32% as of 11/14/2014's recent price of $0.11.
If you would have followed this BofA/Merrill's recommendation on DNDN, you would have gained 5863.63% of your investment in 856 days.

Dendreon Corporation discovers and develops immunologically based therapeutic products for the treatment of cancer. Through the use of antigen engineering and proprietary cell separation technologies, Dendreon develops therapeutic vaccines that induce cell-mediated immunity, the body's key defense against cancer. In addition to its products for cancer, Dendreon also intends to pursue the application of its technologies in the fields of autoimmune diseases, allergies and infectious diseases.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/11/2012 10:25 AM Sell
as of 12/31/2012
1 Week down  -0.76 %
1 Month down  -18.87 %
3 Months down  -9.97 %
1 YTD up  19.35 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy